Anhui Kangzheng Kangyuan Pharmaceutical

Anhui Kangzheng Kangyuan Pharmaceutical is a clinical-stage biopharmaceutical company based in Anhui, China, specializing in the development of innovative anti-infective therapies. The company's primary focus is on optimizing the delivery and efficacy of established antibiotic classes through advanced formulation and combination strategies. Its lead program, KK-R002, is a compound small molecule therapy currently in Phase 1 clinical development for the treatment of community-acquired bacterial pneumonia (CABP). KK-R002 combines penicillin-class antibiotics with probenecid, utilizing a proprietary freeze-drying process to enhance stability and therapeutic performance. The company operates research and manufacturing facilities in Anqing and Hefei, positioning itself as an emerging player in the Chinese antibacterial market.